Positions

Overview

  • Introduction:

    Dr. Mayur Narkhede is an assistant professor at the University of Alabama, Birmingham. He completed his residency in Internal Medicine at the Cleveland Clinic Foundation from 2013 to 2016 and a Hematology and Medical Oncology fellowship from Georgetown University in Washington, D.C. He was the chief fellow from 2018 to 2019. He is board-certified in Internal Medicine, Hematology, and Medical Oncology. Dr. Narkhede specialized in the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, and Chronic Lymphocytic Leukemia.

    Clinical Interests:

    Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia.

    Research: Dr. Narkhede is an active clinical and translational researcher focusing on lymphoid malignancies and Chronic Lymphocytic Leukemia. He is a principal investigator for multiple phase 1 and phase 2 clinical trials conducted at UAB. In addition, his research interest also involves studying imaging and biochemical biomarkers of treatment response and toxicities in non-Hodgkin lymphomas.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Erratum: Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma (Blood Adv. (2022) 6:14 (4122-4131) DOI: 10.1182/bloodadvances.2022007247).  Blood Advances.  6:6039. 2022
    2022 Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.  Clinical Lymphoma, Myeloma and Leukemia.  22:825-834. 2022
    2022 Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.  Blood Advances.  6:4122-4131. 2022
    2022 Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.  Blood.  139:2499-2511. 2022
    2021 B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines.  Journal of the National Comprehensive Cancer Network : JNCCN.  19:1218-1230. 2021
    2021 CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges..  Annals of translational medicine.  9:1036. 2021
    2020 Copanlisib in the treatment of non-Hodgkin lymphoma.  Future Oncology.  16:1947-1955. 2020
    2020 Tafasitamab: Monoclonal antibody targeting CD19 Treatment of B-cell malignancies.  Drugs of the Future.  45:641-651. 2020
    2019 Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia.  JAMA Network Open.  2:e1916326. 2019
    2019 Targeting Biology in Non-Hodgkin Lymphoma 2019
    2018 Determining the sequence of novel therapies in the treatment of relapsed Hodgkin’s lymphoma.  Expert Review of Hematology.  11:773-780. 2018
    2018 Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma.  Clinical Lymphoma, Myeloma and Leukemia.  18:447-451. 2018
    2018 Primary effusion lymphoma: Current perspectives.  OncoTargets and Therapy.  11:3747-3754. 2018
    2017 The association of histologic grade with acute graft-versus-host disease response and outcomes.  American Journal of Hematology.  92:683-688. 2017
    2017 Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.  PLoS One.  12. 2017
    2016 Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.  Leukemia.  30:2214-2220. 2016

    Principal Investigator On

    Investigator On

  • A Multicenter Retrospective Analysis of Treatment Patterns and Outcomes in Patients with Rare T-Cell Lymphoma Subtypes  awarded by Memorial Sloan-Kettering Cancer Center
  • A Multicenter Retrospective Analysis of Treatment Patterns and Outcomes in Patients with Rare T-Cell Lymphoma Subtypes  awarded by NHS GREATER GLASGOW AND CLYDE
  • Determinants of Efficacy and Toxicities among Patients with Lymphoid and Histiocytic Disorders  awarded by Memorial Sloan-Kettering Cancer Center
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by INNATE PHARMA
  • Private Grant  awarded by AFFIMED GMBH
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by ARTIVA BIOTHERAPEUTICS INC
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by INNATE PHARMA
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by VIRACTA INC
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by I-MAB BIOPHARMA US LIMITED
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • UAB 1923: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) study  awarded by City of Hope

    • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Maharashtra University of Health Sciences 2012

    • Full Name

  • Mayur Narkhede